ClinicalTrials.gg
CompletedNCT05047263FIND-CKDUpdated Feb 13, 2026

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

A Phase 3 interventional study of Finerenone (BAY94-8862) and Placebo in Non-diabetic Chronic Kidney Disease, sponsored by Bayer. Completed at 326 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,584
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD.

In this trial, the researchers want to learn if finerenone helps to slow down the worsening of the participants' non-diabetic CKD compared to a placebo. A placebo looks like a trial treatment but does not have any medicine in it. The trial will include about 1,580 men and women who are at least 18 years old.

The participants will take finerenone or a placebo once a day as tablets by mouth. All of the participants will also continue to take their current medicine for their CKD. The participants will be in the trial for up to about 50 months.

During the trial, the doctors will collect blood and urine samples and check the participants' health. The participants will also answer questions about how they are feeling and what adverse events they are having. An adverse event is a medical problem that happens during the trial. Doctors keep track of all adverse events that happen in trials, even if they do not think the adverse events might be related to the trial treatments.

02

Conditions studied

  • Non-diabetic Chronic Kidney Disease
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of chronic kidney disease and:

    • Urine albumin/creatinine ratio (UACR) of ≥ 200 but ≤ 3500 mg/g and estimated (eGFR) ≥ 25 but \< 90 mL/min/1.73m\^2 at screening, and
    • Documentation of albuminuria/proteinuria in the participant's medical records at least 3 months prior to screening.
  • Stable and maximum tolerated labeled dose of an Angiotensin-converting enzyme inhibitor (ACEI) or Angiotensin receptor blocker (ARB) for at least 4 weeks prior to screening
  • K+ ≤ 4.8 mmol/L at screening

Exclusion criteria

Exclusion Criteria:

  • Established diagnosis of Type 1 or 2 Diabetes mellitus, or ≥ 6.5% (48 mmol/mol)
  • Autosomal dominant or autosomal recessive polycystic kidney disease
  • Lupus nephritis or anti-neutrophilic cytoplasmic autoantibody (ANCA) -associated vasculitis or any other primary or secondary kidney disease requiring therapy within 6 months prior to screening
  • Symptomatic heart failure with reduced with class 1A indication for Mineralocorticoid receptor antagonists (MRAs)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,584 participants (actual)

Study arms

  • Experimental
    Finerenone (BAY94-8862)

    Participants will receive finerenone.

    Drug: Finerenone (BAY94-8862)

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean rate of change as measured by the total slope of eGFR from baseline to Month-32.

    eGFR: Estimated glomerular filtration rate

    Time frame: From baseline to month 32

Secondary outcomes

  1. Time to the composite of kidney failure, sustained eGFR decline of >= 57%, heart failure hospitalization or Cardiovascular (CV) death

    Time frame: Up to end of study visit (up to approximately 49 months)

  2. Time to the composite of kidney failure or sustained eGFR decline of >= 57%

    Time frame: Up to end of study visit (up to approximately 49 months)

  3. Time to the composite to heart failure hospitalization or CV death

    Time frame: Up to end of study visit (up to approximately 49 months)

  4. Number of participants with Treatment-emergent adverse events (TEAEs), Treatment-emergent serious adverse events (TESAEs) and Adverse events of special interest (AESI)

    Time frame: Up to approximately 50 months

07

Study locations

326 sites
  • Nephrology Consultants, LLC
    Huntsville, Alabama 35805, United States
  • Balboa Research SMO+ - Chula Vista - West
    Chula Vista, California 91910, United States
  • Balboa Research SMO+ - El Centro
    El Centro, California 92243, United States
  • UCLA Clinical and Translational Research Center - Nephrology
    Los Angeles, California 90095, United States
  • Balboa Nephrology Medical Group - Poway
    Poway, California 92064, United States
  • North America Research Institute - San Dimas
    San Dimas, California 91773, United States
  • United Clinical Research & Innovations
    South Gate, California 90280, United States
  • University of Colorado | Renal Research Office
    Aurora, Colorado 80045, United States
  • DaVita Clinical Research | Middlebury, CT
    Middlebury, Connecticut 55404, United States
  • Yale University | Nephrology Clinical Research
    New Haven, Connecticut 06520, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Research Physicians Network Alliance
    Boca Raton, Florida 33431, United States
  • Florida Kidney Physicians - Boca Raton
    Boca Raton, Florida 33487, United States
  • AdventHealth Translational Research Institute
    Orlando, Florida 32804, United States
  • Grady Memorial Hospital - Endocrinology
    Atlanta, Georgia 30303, United States
  • Southeastern Clinical Research Institute, LLC
    Augusta, Georgia 30904, United States
  • Central Georgia Kidney Specialists - Macon
    Macon, Georgia 31201, United States
  • Frenova Renal Research | Boise Kidney and Hypertension
    Meridian, Idaho 83642, United States
  • Northwestern Medicine - Feinberg School of Medicine - Nephrology and Hypertension
    Chicago, Illinois 60611, United States
  • Research by Design, LLC | Chicago, IL
    Chicago, Illinois 60643, United States
  • Nephrology Associates of Northern Illinois and Indiana - Hinsdale
    Hinsdale, Illinois 60521, United States
  • University of Iowa Health Care Medical Center - Cardiology
    Iowa City, Iowa 52242, United States
  • KUMC Clinical and Translational Science Unit - Nephrology
    Kansas City, Kansas 66160, United States
  • Kansas Nephrology Research Institute
    Wichita, Kansas 67214, United States
  • Wichita Nephrology Group, PA
    Wichita, Kansas 67214, United States
  • Northwest Louisiana Nephrology - Shreveport - 1800 Buckner St.
    Shreveport, Louisiana 71101, United States
  • Johns Hopkins Hospital - Nephrology
    Baltimore, Maryland 21287, United States
  • Tufts Medical Center | Nephrology Department
    Boston, Massachusetts 02111, United States
  • DaVita Clinical Research | Edina, MN
    Edina, Minnesota 55435, United States
  • University Hospital - UMMC - Nephrology
    Jackson, Mississippi 39216, United States
  • Clinical Research Consultants, a JCCT Company
    Kansas City, Missouri 64111, United States
  • St. Louis Heart and Vascular, PC - Christian Hospital Office
    St Louis, Missouri 63136, United States
  • UNM Clinical and Translational Science Center - Nephrology
    Albuquerque, New Mexico 87131, United States
  • Mountain Kidney & Hypertension Associates
    Asheville, North Carolina 28801, United States
  • UNC Hospitals Outpatient Center at Eastowne - Nephrology
    Chapel Hill, North Carolina 27514, United States
  • East Carolina University | Nephrology & Hypertension
    Greenville, North Carolina 27834, United States
  • Eastern Nephrology Associates | Wilmington
    Wilmington, North Carolina 28401, United States
  • UH Cleveland Medical Center - Nephrology
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic | Urological and Kidney Department
    Cleveland, Ohio 44195, United States
  • Northeast Clinical Research Center | Bethlehem, PA
    Bethlehem, Pennsylvania 18017, United States
  • Geisinger Medical Center - Nephrology
    Danville, Pennsylvania 17822, United States
  • Temple Health - Nephrology
    Philadelphia, Pennsylvania 19140, United States
  • South Carolina Clinical Reserach
    Orangeburg, South Carolina 29118, United States
  • Knoxville Kidney Center, PLLC
    Knoxville, Tennessee 37923, United States
  • Vanderbilt University Medical Center - Nephrology Clinical Trials Center
    Nashville, Tennessee 37232, United States
  • Dallas Renal Group - Medical City
    Dallas, Texas 75230, United States
  • El Paso Medical Research Institute (MedResearch Inc) | El Paso, TX
    El Paso, Texas 79902, United States
  • DaVita Clinical Research | Houston, TX
    Houston, Texas 77054, United States
  • Gamma Medical Research, Inc.
    McAllen, Texas 78503, United States
  • Texas Diabetes Institute - Renal Clinic
    San Antonio, Texas 78207, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212, United States
  • DaVita Clinical Research | North Houston, TX
    Shenandoah, Texas 77384, United States
  • University of Utah School of Medicine | Kidney Research Clinic
    Salt Lake City, Utah 84132, United States
  • Utah Kidney Research Institute | Salt Lake City, UT
    South Salt Lake, Utah 84115, United States
  • Nephrology Associates of Northern Virginia - Fair Oaks
    Fairfax, Virginia 22033, United States
  • Mendez Center For Clinical Research | Woodbridge, VA
    Woodbridge, Virginia 22192, United States
  • Providence Medical Research Center
    Spokane Valley, Washington 99204, United States
  • Asociacion de Fomento y Sala de Primeros Auxilios Alberto Mignaburu | Berazategui, Argentina
    Berazategui, Buenos Aires B1837, Argentina
  • Centro de Investigaciones Metabolicas | Ciudad de Autonoma de Buenos Aires, Argentina
    Ciudad Autónoma de Buenos Aire, Buenos Aires C1056ABI, Argentina
  • Centro de Investigaciones Medicas Lanus | Buenos Aires, Argentina
    Lanus, Buenos Aires B1824, Argentina
  • Instituto de Investigaciones Clinicas de Mar del Plata | Mar del Plata, Argentina
    Mar del Plata, Buenos Aires B7600FZ0, Argentina
  • CEDIC Centro de Investigación Clínica | Buenos Aires, Argentina
    CABA, Ciudad Auton. de Buenos Aires C1018DES, Argentina
  • Centro de Rehabilitacion Cardiovascular | San Luis, Argentina
    San Luis, San Luis Province D5700CGR, Argentina
  • Centro de Investigación y Prevención Cardiovascular
    Buenos Aires, C1061AAS, Argentina
  • Clinica Privada Velez Sarsfield
    Córdoba, X5016KET, Argentina
  • Clinica de Nefrologia Urologia y Enfermedades Cardiovascular
    Santa Fe, 3000, Argentina
  • Centro de Investigaciones Clinicas del Litoral | Santa Fe, Argentina
    Santa Fe, S3000FWO, Argentina
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Illawarra Shoalhaven Local Health District
    Wollongong, New South Wales 2500, Australia
  • Sunshine Coast University Hospital
    Birtinya, Queensland 4575, Australia
  • Princess Alexandra Hospital Australia
    Woolloongabba, Queensland 4102, Australia
  • Eastern Health Integrated Renal Service
    Box Hill, Victoria 3128, Australia
  • Melbourne Renal Research Group
    Reservoir, Victoria 3073, Australia
  • Sunshine Hospital
    St Albans, Victoria 3021, Australia
  • AZ Groeninge Campus Kennedylaan | Nephrology
    Kortrijk, West-Vlaanderen 8500, Belgium
  • CU Saint-Luc/UZ St-Luc
    Bruxelles - Brussel, 1200, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • CHU de Liège
    Liège, 4000, Belgium
  • AZ Delta / Nephrology
    Roeselare, 8800, Belgium
  • Medical Center ''4Life''
    Burgas, Burgas Province 8000, Bulgaria
  • Viva Phoenix Medical Center | Clinical Trials Department
    Dobrich, Dobrich Province 9300, Bulgaria
  • Medical Center Hera | Montana Branch
    Montana, Montana Province 3400, Bulgaria
  • Multiprofile Hospital for Active Treatment Sveti Georgi OOD, Pernik - Department of Cardiology
    Pernik, Pernik Province 2300, Bulgaria
  • Diagnostic-Consultative Center XX | Nephrology Department
    Sofia, Sofia City Province 1618, Bulgaria
  • Medical Center Zara-Med EOOD | Nephrology Department
    Stara Zagora, Stara Zagora Province 6010, Bulgaria
  • Multiprofile Hospital for Active Treatment St. Ivan Rilski - Gorna Oryahovitsa | Nephrology Department
    Gorna Oryahovitsa, Veliko Tarnovo Province 5100, Bulgaria
  • Medical Center ''Nevromedics''
    Veliko Tarnovo, Veliko Tarnovo Province 5600, Bulgaria
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui MISSING, China
  • The Second Hospital of Anhui medical university
    Hefei, Anhui 230601, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730030, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong 510280, China
  • The First Affiliated Hospital of Guangzhou University of TCM
    Guangzhou, Guangdong 510405, China
  • The First Affiliated Hospital of Jinan University
    Guangzhou, Guangdong 510630, China
  • Huizhou Central People's Hospital
    Huizhou, Guangdong 516001, China
  • Jiangmen Wuyi Hospital of traditional Chinese Medicine
    Jiangmen, Guangdong 529099, China
  • Liuzhou Worker's Hospital
    Liuzhou, Guangxi 545005, China
  • People's Hospital of Liuzhou City
    Liuzhou, Guangxi 545006, China

Showing the first 100 of 326 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Jongs N, Smeijer JD, Brinker M, Rethemeier N, Schloemer P, Vesterinen P, Goldsbury D, Dizayee S, Mares JW, Perkovic V; FIND-CKD Investigators. Finerenone in Persons with Chronic Kidney Disease without Diabetes. N Engl J Med. 2026 Jun 4. doi: 10.1056/NEJMoa2604625. Online ahead of print. PubMed 42246672 ↗
  • Neuen BL, Perkovic V, Agarwal R, Cherney DZI, Lam CSP, Wanner C, Tuttle KR, Sarafidis P, Barratt J, Burgner A, Chen X, Chew-Wong A, Dobronravov VA, Floege J, McCafferty K, Nangaku M, Packham D, Papachristou E, Pergola PE, Speeckaert MM, Subbiah A, Tang SCW, Tang S, Yeo SC, Jongs N, Smeijer JD, Berger M, Brinker M, Dayoub R, Elliott J, Li N, Mueller K, Rethemeier N, Finkelsztein MY, Heerspink HJL; FIND-CKD Investigators. Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial. JAMA. 2026 Jun 5:e269923. doi: 10.1001/jama.2026.9923. Online ahead of print. PubMed 42246414 ↗
  • Ostrominski JW, Filippatos G, Claggett BL, Miao ZM, Desai AS, Jhund PS, Henderson A, Rohwedder K, Brinker MD, Scalise A, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD, Vaduganathan M. Effect of Finerenone on Morbidity and Mortality in CKD. J Am Soc Nephrol. 2026 Feb 1;37(2):312-325. doi: 10.1681/ASN.0000000823. Epub 2025 Sep 12. PubMed 40938666 ↗
  • Li Y, Feng J, Guo X, Zhang W, Yang T, Guan T, Xu B. Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study. BMC Nephrol. 2025 Jul 1;26(1):323. doi: 10.1186/s12882-025-04241-w. PubMed 40597854 ↗
  • Zachariah T, Radhakrishnan J. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease. Clin J Am Soc Nephrol. 2024 Nov 1;19(11):1499-1512. doi: 10.2215/CJN.0000000000000540. Epub 2024 Jul 22. PubMed 39037799 ↗

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Dec 2025, 51 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2021
First posted
Sep 17, 2021
StartActual
Sep 21, 2021
Primary completionActual
Dec 31, 2025
CompletionActual
Feb 2, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05047263
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Sep 21, 2021
Primary completion
Dec 31, 2025
Completion
Feb 2, 2026
Last update
Feb 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion